A Look Back at Branded Pharmaceuticals Stocks' Q4 Earnings: Collegium Pharmaceutical (NASDAQ:COLL) Vs The Rest Of The Pack
The branded pharmaceutical industry relies on a high-cost, high-reward business model, driven by substantial investments in research and development to create innovative, patent-protected drugs. Successful products can generate significant revenue streams over their patent life, and the larger a roster of drugs, the stronger a moat a company enjoys. However, the business model is inherently risky, with high failure rates during clinical trials, lengthy regulatory approval processes, and intense competition from generic and biosimilar manufacturers once patents expire. These challenges, combined with scrutiny over drug pricing, create a complex operating environment. Looking ahead, the industry is positioned for tailwinds from advancements in precision medicine, increasing adoption of AI to enhance drug development efficiency, and growing global demand for treatments addressing chronic and rare diseases. However, headwinds include heightened regulatory scrutiny, pricing pressures from governments and insurers, and the looming patent cliffs for key blockbuster drugs. Patent cliffs bring about competition from generics, forcing branded pharmaceutical companies back to the drawing board to find the next big thing.
The 11 branded pharmaceuticals stocks we track reported a mixed Q4. As a group, revenues beat analysts' consensus estimates by 1.3%.
In light of this news, share prices of the companies have held steady as they are up 1.4% on average since the latest earnings results.
Pioneering abuse-deterrent technology in a field plagued by addiction concerns, Collegium Pharmaceutical (NASDAQ:COLL) develops and markets specialty medications for treating moderate to severe pain, including abuse-deterrent opioid formulations.
Collegium Pharmaceutical reported revenues of $181.9 million, up 21.5% year on year. This print exceeded analysts' expectations by 1%. Overall, it was a strong quarter for the company with a solid beat of analysts' EPS estimates and full-year revenue guidance meeting analysts' expectations.
'2024 was a year of strong execution for Collegium, marked by robust performance in our pain portfolio and the addition of Jornay PM, establishing our presence in neuropsychiatry and reaffirming our commitment to helping improve the lives of people living with serious medical conditions. This was made possible thanks to the dedication of our talented team,' said Vikram Karnani, President and Chief Executive Officer.
The stock is up 6.2% since reporting and currently trades at $30.20.
Is now the time to buy Collegium Pharmaceutical? Access our full analysis of the earnings results here, it's free.
With a diverse portfolio of eight FDA-approved medications targeting neurological conditions, Supernus Pharmaceuticals (NASDAQ:SUPN) develops and markets treatments for central nervous system disorders including epilepsy, ADHD, Parkinson's disease, and migraine.
Supernus Pharmaceuticals reported revenues of $174.2 million, up 6% year on year, outperforming analysts' expectations by 12.2%. The business had a very strong quarter with an impressive beat of analysts' EPS estimates and full-year operating income guidance topping analysts' expectations.
Supernus Pharmaceuticals achieved the biggest analyst estimates beat among its peers. Although it had a fine quarter compared to its peers, the market seems unhappy with the results as the stock is down 4.6% since reporting. It currently trades at $31.32.
Is now the time to buy Supernus Pharmaceuticals? Access our full analysis of the earnings results here, it's free.
Originally spun off from Pfizer in 2013 as the world's largest pure-play animal health company, Zoetis (NYSE:ZTS) discovers, develops, and sells medicines, vaccines, diagnostic products, and services for pets and livestock animals worldwide.
Zoetis reported revenues of $2.32 billion, up 4.7% year on year, in line with analysts' expectations. It was a softer quarter as it posted a significant miss of analysts' full-year EPS guidance estimates.
As expected, the stock is down 6.9% since the results and currently trades at $161.91.
Read our full analysis of Zoetis's results here.
Pioneering a unique business model in the pharmaceutical industry since 1996, Royalty Pharma (NASDAQ:RPRX) acquires rights to receive portions of sales from successful biopharmaceutical products, providing funding to drug developers without conducting research itself.
Royalty Pharma reported revenues of $594 million, flat year on year. This print lagged analysts' expectations by 1.9%. Overall, it was a slower quarter for the company.
The stock is flat since reporting and currently trades at $31.77.
Read our full, actionable report on Royalty Pharma here, it's free.
Spun off from Merck in 2021 to create a company dedicated to addressing unmet needs in women's health, Organon (NYSE:OGN) is a global healthcare company focused on improving women's health through prescription therapies, medical devices, biosimilars, and established medicines.
Organon reported revenues of $1.59 billion, flat year on year. This number surpassed analysts' expectations by 0.9%. However, it was a slower quarter as it logged full-year revenue guidance missing analysts' expectations.
Organon had the slowest revenue growth among its peers. The stock is down 3.1% since reporting and currently trades at $14.23.
Read our full, actionable report on Organon here, it's free. Want to invest in winners with rock-solid fundamentals? Check out our Hidden Gem Stocks and add them to your watchlist. These companies are poised for growth regardless of the political or macroeconomic climate.
Join Paid Stock Investor Research
Help us make StockStory more helpful to investors like yourself. Join our paid user research session and receive a $50 Amazon gift card for your opinions. Sign up here.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
3 hours ago
- Business Wire
HROW Investors Have Opportunity to Join Harrow, Inc. Fraud Investigation with the Schall Law Firm
LOS ANGELES--(BUSINESS WIRE)-- The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Harrow, Inc. ('Harrow' or 'the Company') (NASDAQ: HROW) for violations of the securities laws. The investigation focuses on whether the Company issued false and/or misleading statements and/or failed to disclose information pertinent to investors. Harrow announced its financial results for Q1 2025 on May 8, 2025. The Company reported revenues that missed consensus estimates and adjusted EBITDA of -$1.9 million. Based on this news, shares of Harrow fell by more than 4%. If you are a shareholder who suffered a loss, click here to participate. We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at or by email at bschall@ The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation. This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.
Associated Press
4 hours ago
- Associated Press
Kessler Topaz Meltzer & Check, LLP Reminds MSTR Shareholders of Deadline in Securities Fraud Class Action Lawsuit Filed Against MicroStrategy Incorporated d/b/a Strategy (MSTR)
RADNOR, PA - July 6, 2025 ( NEWMEDIAWIRE ) - The law firm of Kessler Topaz Meltzer & Check, LLP ( ) informs investors that a securities class action lawsuit has been filed against MicroStrategy Incorporated d/b/a Strategy ('Strategy') ( NASDAQ: MSTR ) on behalf of those who purchased or otherwise acquired Strategy securities between April 30, 2024, and April 4, 2025, inclusive (the 'Class Period'). The lead plaintiff deadline is July 15, 2025. CONTACT KESSLER TOPAZ MELTZER & CHECK, LLP: If you suffered Strategy losses, you may CLICK HERE or copy and paste the following link into your browser: You can also contact attorney Jonathan Naji, Esq. by calling (484) 270-1453 or by email at [email protected]. DEFENDANTS' ALLEGED MISCONDUCT: The complaint alleges that, throughout the Class Period, Defendants made materially false and misleading statements regarding Strategy's business, operations, and prospects. Specifically, Defendants made false and/or misleading statements and/or failed to disclose that: (1) the anticipated profitability of Strategy's bitcoin-focused investment strategy and treasury operations was overstated; (2) the various risks associated with bitcoin's volatility and the magnitude of losses Strategy could recognize on the value of its digital assets following its adoption of ASU 2023-08 were understated; and (3) as a result, Defendants' public statements were materially false and misleading at all relevant times. THE LEAD PLAINTIFF PROCESS: Strategy investors may, no later than July 15, 2025, seek to be appointed as a lead plaintiff representative of the class through Kessler Topaz Meltzer & Check, LLP or other counsel, or may choose to do nothing and remain an absent class member. A lead plaintiff is a representative party who acts on behalf of all class members in directing the litigation. The lead plaintiff is usually the investor or small group of investors who have the largest financial interest and who are also adequate and typical of the proposed class of investors. The lead plaintiff selects counsel to represent the lead plaintiff and the class and these attorneys, if approved by the court, are lead or class counsel. Your ability to share in any recovery is not affected by the decision of whether or not to serve as a lead plaintiff. Kessler Topaz Meltzer & Check, LLP encourages Strategy investors who have suffered significant losses to contact the firm directly to acquire more information. CLICK HERE TO SIGN UP FOR THE CASE OR GO TO: ABOUT KESSLER TOPAZ MELTZER & CHECK, LLP: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country and around the world. The firm has developed a global reputation for excellence and has recovered billions of dollars for victims of fraud and other corporate misconduct. All of our work is driven by a common goal: to protect investors, consumers, employees and others from fraud, abuse, misconduct and negligence by businesses and fiduciaries. The complaint in this action was not filed by Kessler Topaz Meltzer & Check, LLP. For more information about Kessler Topaz Meltzer & Check, LLP please visit CONTACT: Kessler Topaz Meltzer & Check, LLP Jonathan Naji, Esq. (484) 270-1453 280 King of Prussia Road Radnor, PA 19087 [email protected] May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes. View the original release on
Business Insider
4 hours ago
- Business Insider
NVDA, TSLA, PLTR: Retail Investors Traded a Record $6.6 Trillion of Stocks in Year's First Half
Uncertainty, volatility and relief led retail investors around the world to trade a record $6.6 trillion worth of stocks during the first half of 2025. Don't Miss TipRanks' Half-Year Sale Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week. Tariffs, market volatility, ongoing wars in Europe and the Middle East, and political tensions within the U.S. all conspired to get investors to buy and sell a record amount of equities in the year's first half. According to data from Nasdaq (NDAQ), individual retail investors cumulatively bought $3.4 trillion worth of stocks over the first six months of 2025. At the same time, the retail crowd sold $3.2 trillion worth of stocks, bringing the total traded to $6.6 trillion, a previously unheard-of sum. Among the most widely bought and sold securities between January and June were the stocks of chipmaker Nvidia (NVDA), electric vehicle maker Tesla (TSLA), and data analytics company Palantir (PLTR). Bear to Bull Even more dramatic, most of the buying and selling that occurred in the year's first half happened in April and May after the tariff announcements from U.S. President Donald Trump rattled global markets and ignited fears of a global trade war and economic recession. Those fears have since abated as the Trump administration has struck trade deals with countries such as the United Kingdom and China, and backed down on many of its retaliatory tariff threats. Nasdaq says that some retail investors found this past spring 'the toughest investment climate' they ever experienced. Yet the initial concerns have now given way to bullish sentiment as tariff and trade war fears subside. Is NVDA Stock a Buy? The stock of Nvidia has a consensus Strong Buy rating among 40 Wall Street analysts. That rating is based on 35 Buy, four Hold, and one Sell recommendations assigned in the last three months. The average NVDA price target of $175.69 implies 10.26% upside from current levels.
